--Company To Also Webcast a Briefing of the Results--
PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of patients with
hypercholesterolemia, today announced that full results of the Phase 2
ETC-1002-006 clinical study in patients with hypercholesterolemia and a
history of statin intolerance will be presented in an oral presentation
session by principal investigator Paul D. Thompson, M.D., on November 18
at the 2013 Scientific Sessions of the American Heart Association in
Dallas. Later in the day, the Company will webcast a briefing of the
results.
The Phase 2 proof-of-concept study was designed to evaluate the LDL-C
lowering efficacy, safety and tolerability of ETC-1002 compared with
placebo in patients with hypercholesterolemia and a history of
intolerance to two or more statins. In June 2013, Esperion previously
announced positive topline results from this study, which demonstrated
that ETC-1002 lowered LDL-C greater than 30 percent and was well
tolerated.
Details of the oral presentation follow:
-
Title: ETC-1002 Lowered LDL-C and Was Well Tolerated in
Hypercholesterolemia Patients with Statin Intolerance
-
Presenter: Paul D. Thompson, M.D., Director of Cardiology,
Cardiovascular Research at Hartford Hospital, and Professor of
Medicine at the University of Connecticut
-
Date/Time: Monday, November 18, 2:30-2:45 p.m. Central Time
-
Session: George L. Duff Memorial Lecture and Therapeutic Approaches
for Treating Dyslipidemia
-
Location: Room D167
Webcast Briefing Details
Esperion will host a briefing on Monday, November 18, from 7:00 to 9:00
p.m. Central Time separate from the AHA Scientific Sessions in Dallas.
During the event, the Company will provide an update on its recent
business progress, and the featured guest, Dr. Thompson, will provide a
recap of the ETC-1002-006 full results. A live webcast of the event will
be available via the Esperion website at www.esperion.com.
A replay of the webcast will be available on the Company's website for
90 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule therapy designed to lower levels of
LDL-C and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and has initiated a robust
Phase 2b clinical program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of ETC-1002.
Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that could
cause Esperion's actual results to differ significantly from those
projected, including, without limitation, the risk that unanticipated
developments could interfere with the development (and
commercialization) of ETC-1002, as well as other risks detailed in
Esperion's filings with the Securities and Exchange Commission,
including our Quarterly Report on Form 10-Q filed with Securities and
Exchange Commission on November 6, 2013. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only as of
the date of this release. Esperion disclaims any obligation or
undertaking to update or revise any forward-looking statements contained
in this press release, other than to the extent required by law.
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media